SG11202006296YA - Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors - Google Patents

Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors

Info

Publication number
SG11202006296YA
SG11202006296YA SG11202006296YA SG11202006296YA SG11202006296YA SG 11202006296Y A SG11202006296Y A SG 11202006296YA SG 11202006296Y A SG11202006296Y A SG 11202006296YA SG 11202006296Y A SG11202006296Y A SG 11202006296YA SG 11202006296Y A SG11202006296Y A SG 11202006296YA
Authority
SG
Singapore
Prior art keywords
dihydrobenzofuran
inden
analogs
cardiac sarcomere
inhibitors
Prior art date
Application number
SG11202006296YA
Other languages
English (en)
Inventor
Chihyuan Chuang
Bradley P Morgan
Mark Vanderwal
Wenyue Wang
Luke W Ashcraft
Original Assignee
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics Inc filed Critical Cytokinetics Inc
Publication of SG11202006296YA publication Critical patent/SG11202006296YA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/061,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/027Organoboranes and organoborohydrides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG11202006296YA 2018-01-19 2019-01-18 Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors SG11202006296YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862619643P 2018-01-19 2018-01-19
US201862745724P 2018-10-15 2018-10-15
PCT/US2019/014344 WO2019144041A1 (en) 2018-01-19 2019-01-18 Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors

Publications (1)

Publication Number Publication Date
SG11202006296YA true SG11202006296YA (en) 2020-08-28

Family

ID=65324663

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202006296YA SG11202006296YA (en) 2018-01-19 2019-01-18 Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors

Country Status (20)

Country Link
US (3) US10836755B2 (es)
EP (1) EP3740481B1 (es)
JP (2) JP7401439B2 (es)
KR (1) KR20200112895A (es)
CN (3) CN111757875B (es)
AU (1) AU2019208331B2 (es)
BR (1) BR112020014428A2 (es)
CA (1) CA3087283A1 (es)
CL (2) CL2020001871A1 (es)
CO (1) CO2020009225A2 (es)
DK (1) DK3740481T3 (es)
EC (1) ECSP20044709A (es)
IL (1) IL276094B2 (es)
MA (1) MA51620A (es)
MX (2) MX2020007532A (es)
PH (1) PH12020551090A1 (es)
SG (1) SG11202006296YA (es)
TW (1) TWI835770B (es)
UY (1) UY38057A (es)
WO (1) WO2019144041A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10836755B2 (en) 2018-01-19 2020-11-17 Cytokinetics, Inc. Cardiac sarcomere inhibitors
EP3814343B1 (en) * 2018-06-26 2023-01-11 Cytokinetics, Inc. Cardiac sarcomere inhibitors
JP7438148B2 (ja) * 2018-06-26 2024-02-26 サイトキネティックス, インコーポレイテッド 心臓サルコメア阻害剤
KR20210068422A (ko) 2018-08-31 2021-06-09 싸이토키네틱스, 인코포레이티드 심장 근절 억제제
JP2022530989A (ja) * 2019-05-03 2022-07-05 プラクシス プレシジョン メディシンズ, インコーポレイテッド Kcnt1阻害剤および使用する方法
CA3144974A1 (en) * 2019-07-17 2021-01-21 Norma TOM Polymorphs of (r)-n-(5-(5-isopropyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-2-methyl-2h-tetrazole-5-carboxamide
DK3999180T3 (da) * 2019-07-17 2024-05-21 Cytokinetics Inc Polymorfer af (R)-N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1 -methyl-1H-pyrazol-4-carboxamid
ES2974542T3 (es) 2019-07-17 2024-06-27 Cytokinetics Inc Formulaciones orales de inhibidores del sarcómero cardíaco
CN112094253B (zh) * 2020-09-10 2023-01-10 株式会社大熊制药 用于制备sglt抑制剂中间体的合成方法
AR125026A1 (es) 2021-03-04 2023-05-31 Cytokinetics Inc Inhibidores del sarcómero cardíaco
AU2022312506A1 (en) 2021-07-16 2024-02-01 Cytokinetics, Inc. Methods for treating hypertrophic cardiomyopathy
TW202315619A (zh) 2021-08-03 2023-04-16 美商胞質動力學公司 用於製備阿非卡坦(aficamten)之方法
US20230338378A1 (en) 2022-04-26 2023-10-26 MyoKardia, Inc. Methods of Administering Myosin Inhibitors
US20240091203A1 (en) 2022-07-20 2024-03-21 Cytokinetics, Incorporated Methods for treating non-obstructive hypertrophic cardiomyopathy
WO2024031016A1 (en) 2022-08-04 2024-02-08 Cytokinetics, Incorporated Methods for treating obstructive hypertrophic cardiomyopathy
WO2024040190A1 (en) 2022-08-18 2024-02-22 Cytokinetics, Incorporated Indane and coumaran derivatives as fast skeletal muscle myosin inhibitors
WO2024134498A1 (en) 2022-12-22 2024-06-27 Assia Chemical Industries Ltd. Solid state forms of aficamten and process for preparation thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US633499A (en) 1899-06-29 1899-09-19 Oil Well Supply Co Coupling for pipes, tubes, or casings.
WO1995026325A2 (en) 1994-03-25 1995-10-05 Isotechnika Inc. Enhancement of the efficacy of drugs by deuteration
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US5919785A (en) 1996-04-03 1999-07-06 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU2002365057A1 (en) 2001-12-21 2003-07-30 Cytokinetics, Inc. Compositions and methods for treating heart failure
MXPA05007513A (es) * 2003-01-14 2005-09-21 Cytokinetics Inc Compuestos, composiciones y metodos.
EP1605752B1 (en) 2003-03-27 2011-09-14 Cytokinetics, Inc. Sulfonamides for the treatment of congestive heart failure, their compositions and uses.
RU2006101541A (ru) * 2003-06-20 2006-06-10 Амген Инк. (US) Производные пиперазина и способ их применения
ES2686357T3 (es) * 2004-06-17 2018-10-17 Cytokinetics, Inc. Compuestos, composiciones y procedimientos
US20060173183A1 (en) * 2004-12-31 2006-08-03 Alantos Pharmaceuticals, Inc., Multicyclic bis-amide MMP inhibitors
CA2604916A1 (en) 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
US7718657B2 (en) * 2005-12-16 2010-05-18 Cytokinetics, Inc. Certain indanyl urea modulators of the cardiac sarcomere
RU2318818C1 (ru) 2006-04-12 2008-03-10 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты)
SA08290245B1 (ar) 2007-04-23 2012-02-12 استرازينيكا ايه بي مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم
US20090192168A1 (en) 2008-01-04 2009-07-30 Alex Muci Compounds, Compositions and Methods
US20110275673A1 (en) * 2008-09-19 2011-11-10 Yibin Xiang Inhibitors of sphingosine kinase 1
MA33358B1 (fr) 2009-05-15 2012-06-01 Novartis Ag Arylpyridine en tant qu'inhibiteurs de l'aldostérone synthase
US8592426B2 (en) * 2011-01-24 2013-11-26 Hoffmann—La Roche Inc. Aryl-benzocycloalkyl amide derivatives
US8759380B2 (en) 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
JP6111268B2 (ja) 2012-01-20 2017-04-05 アクテリオン ファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd P2x7受容体アンタゴニストとしての複素環アミド誘導体
WO2014205234A1 (en) 2013-06-21 2014-12-24 MyoKardia, Inc. Cycloalkyl-substituted pyrimidinedione compounds
MY190860A (en) 2013-06-21 2022-05-12 Myokardia Inc Pyrimidinedione compounds against cardiac conditions
US9663516B2 (en) 2014-12-18 2017-05-30 MyoKardia, Inc. Bicyclic-pyrimidinedione compounds
FI3247707T3 (fi) 2015-01-22 2023-08-22 Myokardia Inc Sydänhäiriöiden kuten dilatoivan kardiomyopatian (dcm) hoitoon hyödyllisiä 4-metyylisulfonyylisubstituoituja piperidiiniureayhdisteitä
JP2019507110A (ja) 2015-12-17 2019-03-14 シンジェンタ パーティシペーションズ アーゲー 殺微生物性オキサジアゾール誘導体
US20190364899A1 (en) 2015-12-18 2019-12-05 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
EP3448519A4 (en) 2016-04-29 2020-01-22 Board Of Regents, The University Of Texas System SIGMA RECEIVER BINDERS
US11066396B2 (en) 2016-06-23 2021-07-20 Merck Sharp & Dohme Corp. 3-aryl- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histonedeacetylase 6 (HDAC6) inhibitors
CA3037537C (en) 2016-09-27 2021-06-15 Merck Sharp & Dohme Corp. Chromane, isochromane and dihydroisobenzofuran derivatives as mglur2-negative allosteric modulators, compositions, and their use
WO2018089433A1 (en) 2016-11-08 2018-05-17 Navitor Pharmaceuticals, Inc. PHENYL mTORC INHIBITORS AND USES THEREOF
US20200000822A1 (en) 2017-02-23 2020-01-02 Board Of Regents, The University Of Texas System Methods of treatment for cancer, sterol homeostasis, and neurological diseases
AU2018311974B2 (en) 2017-08-04 2024-03-07 MyoKardia, Inc. Mavacamten for use in the treatment of hypertrophic cardiomyopathy
US10836755B2 (en) 2018-01-19 2020-11-17 Cytokinetics, Inc. Cardiac sarcomere inhibitors
EP3762368B1 (en) 2018-03-08 2022-01-26 Incyte Corporation Aminopyrazine diol compounds as pi3k-y inhibitors
EP3814343B1 (en) 2018-06-26 2023-01-11 Cytokinetics, Inc. Cardiac sarcomere inhibitors
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス, インコーポレイテッド 心臓サルコメア阻害剤
KR20210068422A (ko) 2018-08-31 2021-06-09 싸이토키네틱스, 인코포레이티드 심장 근절 억제제
MX2023002024A (es) 2020-08-28 2023-05-10 Myokardia Inc Métodos de tratamiento con modulador de miosina.

Also Published As

Publication number Publication date
AU2019208331A1 (en) 2020-07-16
CO2020009225A2 (es) 2020-08-10
CA3087283A1 (en) 2019-07-25
IL276094B2 (en) 2023-08-01
CN117964573A (zh) 2024-05-03
UY38057A (es) 2019-08-30
PH12020551090A1 (en) 2021-09-01
AU2019208331B2 (en) 2024-05-02
US20210147399A1 (en) 2021-05-20
ECSP20044709A (es) 2020-10-30
JP2021511331A (ja) 2021-05-06
US10836755B2 (en) 2020-11-17
CN111757875B (zh) 2024-01-09
JP2023169374A (ja) 2023-11-29
KR20200112895A (ko) 2020-10-05
US20230119665A1 (en) 2023-04-20
CN117924208A (zh) 2024-04-26
MX2020007532A (es) 2020-09-09
US11472796B2 (en) 2022-10-18
WO2019144041A1 (en) 2019-07-25
MA51620A (fr) 2020-11-25
IL276094A (en) 2020-08-31
IL276094B1 (en) 2023-04-01
CL2020001871A1 (es) 2020-10-23
MX2022014312A (es) 2022-12-07
DK3740481T3 (da) 2024-07-08
EP3740481A1 (en) 2020-11-25
CN111757875A (zh) 2020-10-09
JP7401439B2 (ja) 2023-12-19
BR112020014428A2 (pt) 2020-12-01
CL2022001091A1 (es) 2023-01-20
US20190256504A1 (en) 2019-08-22
TWI835770B (zh) 2024-03-21
TW201940471A (zh) 2019-10-16
EP3740481B1 (en) 2024-06-26

Similar Documents

Publication Publication Date Title
IL276094A (en) Dihydrobezofuran and indan analogues as cardiac sarcomere inhibitors
IL283639A (en) kif18a inhibitors
IL271028A (en) Inhibition of crystal growth of roflumilest
IL281075A (en) Cardiac sarcomere inhibitors
IL284508A (en) Irreversible inhibitors of the MENIN-MLL interaction
SG11202103062UA (en) Inhibitors of vap-1
GB2570161B (en) Simulation of exclusive instructions
IL304110A (en) Keap1–nrf2 protein–protein interaction inhibitors
IL281815A (en) VAP-1 inhibitors
GB201708457D0 (en) Inhibitors of metallo-beta-lactamases
EP3894768C0 (en) METHOD FOR CRYOHARDENING
IL276013A (en) pi4kiiibeta inhibitors
IL281514A (en) O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors
IL277806A (en) Growth inhibitor
GB201708451D0 (en) Inhibitors of metallo-beta-lactamases
ZA202105399B (en) Use of spiropidion
IL277578A (en) New salt forms of URAT-1 inhibitors
SG11202107734TA (en) Controlled tissue anchor spacing
GB201819164D0 (en) Artificial-intelligence-assisted surgery
TWI848972B (zh) 心臟肌小節抑制劑
IL291368A (en) Inhibits expression of methadherin
PT3901141T (pt) Nova forma de isoquinolinossulfonamida
IL265948A (en) Leads to a zygomatic surgical guide
GB201908044D0 (en) Dopamine-B-Hydroxylase inhibitors
GB201905476D0 (en) MAPA4K4 Inhibitors